Masimo Osake

Masimo Rule of 40

Delisted·12.6.2026

40. säännön sääntö yhtiöstä Masimo (MASI) 6.8.2026 päivämäärällä on −6,61 %. Edellisenä vuonna 40. säännön sääntö oli −10,23 % — muutos −35,41 % (korkeampi).

Rule of 40

−6,61 %

YoY

−35,41%

Viimeksi päivitetty:

40. säännön sääntö yhtiöstä Masimo on 2026 −6,61 % . 40. säännön sääntö yhtiöstä Masimo oli 2025 −10,23 % . Se laskee −35,41% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Masimo Osakeanalyysi

Mitä Masimo tekee? Masimo Corporation is an American medical technology company based in Irvine, California. The company was founded in 1989 by Professor Joe Kiani, who is still the chairman and CEO of the company today. With innovative products and advanced technology, Masimo aims to optimize medical diagnostic and treatment procedures to improve patient care. The business model of Masimo Corp focuses on developing and marketing products and solutions for patient monitoring and treatment in hospitals, intensive care facilities, and outpatient clinics. The company relies on high levels of innovation and collaboration with physicians, scientists, and other experts. The goal is to improve existing medical procedures, explore new applications for the technology, and optimize patient care. Masimo Corp's products are divided into different divisions that focus on various aspects of medical care. One example is the "Patient Monitoring" division, which offers various monitoring systems for vital signs such as respiration, pulse, and oxygen saturation. This includes products like the Rad-67 pulse oximeter or the Root patient monitor, which continuously monitor patients during treatment to enhance safety and effectiveness. Another division is "Anesthesia and Sedation," which focuses on solutions for anesthesiologists and intensive care specialists. Masimo Corp offers products such as the SedLine brain monitor or the EMMA main gas monitor, which enable physicians to control anesthesia depth more precisely and reduce the risk of complications. In addition to patient monitoring systems, Masimo Corp also provides solutions for neonatal care. The "Neonatal Care" division includes products like the Masimo Radical-7 pulse oximeter for monitoring premature infants or the Pronto-7 pulse oximeter for fast and accurate monitoring of newborns in the delivery room. Furthermore, Masimo Corp has developed products for monitoring surgical patients. The "Surgical and Minimally Invasive Monitoring" division, for example, offers the MOC-9 monitoring system for precise monitoring of hemodynamics during surgery. A unique product of Masimo Corp is also the Masimo SET sensor, which provides more accurate and reliable measurement of blood oxygen saturation than traditional pulse oximeter sensors. The company has filed over 100 patents worldwide for this technology and has been recognized with numerous awards and accolades. In summary, Masimo Corp is an innovative company specializing in improving medical care through the development and marketing of products for patient monitoring and treatment. With its state-of-the-art technologies and collaboration with experts in medical research, Masimo Corp sets standards for patient safety and treatment effectiveness. Masimo on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Masimo osakkeesta

Yhtiön Masimo 40. säännön sääntö on −6,61 % vuonna 2026.

Eurpoolissa voit löytää 40. säännön sääntö Masimo:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

40. säännön sääntö sanoo, että yrityksen tulojen kasvuvauhti plus voittomarginaali olisi ylitettävä 40 %. Sitä käytetään laajalti SaaS- ja nopeasti kasvavien yritysten arvioimiseen.

Access this data via the Eulerpool API

Laatu — Masimo

Kaikki tunnusluvut — Masimo